Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics


Akero Therapeutics, Inc. (AKRO): $37.45

-2.39 (-6.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AKRO Stock Price Chart Interactive Chart >

Price chart for AKRO

AKRO Price/Volume Stats

Current price $37.45 52-week high $54.88
Prev. close $39.84 52-week low $7.52
Day low $37.40 Volume 1,066,600
Day high $39.82 Avg. volume 596,904
50-day MA $45.03 Dividend yield N/A
200-day MA $32.02 Market Cap 1.76B

Akero Therapeutics, Inc. (AKRO) Company Bio


Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.


AKRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AKRO Latest Social Stream


Loading social stream, please wait...

View Full AKRO Social Stream

Latest AKRO News From Around the Web

Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.

Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up

Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average.

Yahoo | March 22, 2023

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022. “The wins we celebrated in 2022 further solidify our confidence in efruxifermin (EFX) as a potential best-in-class FGF21 analog addressing all core

Yahoo | March 17, 2023

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. “Akero is thrilled to welcome Patrick to the team, especially following last year’s HARMONY study results, which further demonstrate EFX’s potential to treat

Yahoo | January 10, 2023

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA. A live webcast of the Company presentation will be available through the investor r

Yahoo | January 4, 2023

Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program

Akero Therapeutics Inc (NASDAQ: AKRO) completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH) in patients with compensated cirrhosis fibrosis stage 4 (F4). Enrollment is also complete for the expansion cohort, known as Cohort D, evaluating EFX in combination with GLP-1 therapy in patients with fibrosis stage 1-3 (F1-F3) and Type 2 Diabetes. One hundred eighty-two patients have been randomized to receive once-weekly subcutane

Yahoo | December 22, 2022

Read More 'AKRO' Stories Here

AKRO Price Returns

1-mo -15.88%
3-mo -23.34%
6-mo 41.00%
1-year 161.71%
3-year 123.85%
5-year N/A
YTD -31.66%
2022 159.10%
2021 -18.02%
2020 16.24%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7397 seconds.